visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Neurofilament light chain level is a weak risk factor for the development of MS |
Data: | 2016 |
Resum: | To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553. 1 [1,208. 7-1,897. 5] ng/L and CIS-CIS 499. 0 [168. 8-829. 2] ng/L, p < 0. 0001). The strongest associations were with brain parenchymal fraction change (r = −0. 892) and percentage brain volume change (r = −0. 842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1. 009, 95% CI 1. 005-1. 014) and McDonald MS (HR = 1. 009, 95% CI 1. 005-1. 013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1. 005, 95% CI 1. 000-1. 011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes. |
Ajuts: | Instituto de Salud Carlos III RD07-0060 Instituto de Salud Carlos III RD12-0032 Agència de Gestió d'Ajuts Universitaris i de Recerca 2009/SGR-0793 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-1082 Ministerio de Economía y Competitividad PI08-0788 Ministerio de Economía y Competitividad PI12-01313 Ministerio de Economía y Competitividad ISCIII/CP07-00146 Ministerio de Economía y Competitividad ISCIII/CP13-00028 Ministerio de Economía y Competitividad ISCIII/CD09-0363 Ministerio de Economía y Competitividad ISCIII/CM10-00032 |
Nota: | Altres ajuts: T Jens Kuhle was supported by an ECTRIMS Research Fellowship Programme and by the Forschungsfonds of the University of Basel, Switzerland. |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Publicat a: | Neurology, Vol. 87 (september 2016) , p. 1076-1084, ISSN 1526-632X |
9 p, 405.7 KB |